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ANDERSON (1962) reported that the administration of 3-methylcholanthrene
(MC) to newborn rats, or to rat foetuses during the last week of intrauterine life,
reduced their reponsiveness to twice-weekly applications ofMC to the skin starting
when they were 6 weeks of age. In another experiment, she observed that
sarcomas developed at the site of the subcutaneous injection of 1 mg. MC given
when rats were 4 weeks old; rats, similarly treated at birth, failed to develop
sarcomas during a 78 week observation period.
Anderson considered these findings to be consistent with the hypothesis,
proposed by Green (1954), that the chemical induction of cancer involved the
formation of an antigenic carcinogen protein complex and a special antigen-
antibody reaction and that the injection of a carcinogen during the foetal or
neonatal period was associated with the suppression ofantibody formation to this
complex.
It has frequently been demonstrated that tolerance to both soluble and
particulate antigens is induced more readily in newborn rats and mice than in
older animals ofthe same species (Billingham and Brent, 1959; Billingham et al.,
1960). On the other hand, contrary to Anderson's (1962) findings, others have
found newborn animals to be more sensitive than older animals to the effects of
carcinogens (Walters, 1966; Kelly and O'Gara, 1961). O'Gara and Kelly (1963),
however, found that 2-week-old mice were more susceptible to carcinogen treat-
ment, on a mg./kg. basis, than newborn mice, or than 4-week-old or 8-week-old
mice. Roe, Rowson and Salaman (1961) foundthat the administration ofcarcino-
gens during the early neonatal period induced a wide variety of tumours, rarely
or never seen in response to the same carcinogens given later in life. They felt
that the markedsensitivity ofmiceto carcinogens, administered during that period
in which tolerance is most easily induced, argued against Green's hypothesis.
The experiments reported in the present paper were undertaken in an attempt
to define the circumstances in which the administration ofa carcinogen during the
early neonatal period may modify the response ofanimals to subsequent exposure
to the same carcinogen.
MATERIALS AND METHODS
Animals.-Rats of an inbred Wistar strain were used in Experiment I and
random-bred Swiss albino mice from 2 different sources were used in Experiments
II and III. As a precaution against ectromelia, mice were vaccinated on the tail
with sheep lymph when they reached 4 weeks of age.MODIFICATION OF RESPONSE TO CARCINOGENS
Animals of both species were housed in metal cages throughout the experi-
ments, fed cubed diet 41B supplemented with crushed oats, and given water ad
libitum.
Chemicals.-3-Methylcholanthrene (MC) and 3,4-benzopyrene (BP) were
obtained from L. Light and Co. Acetone (AnalaR grade) and Gelatin powder
from British Drug Houses, and trioctanoin (Tricaprylin4 from Eastman Kodak.
Chemicals were administered to neonates either as suspensions in 3 ° aqueous
gelatin or as solutions in Tricaprylin. The former were prepared by adding
acetone solutions ofthe agents to aqueous gelatin and removing the acetone in a
stream ofnitrogen at 560 C.
Techniques of injection of newborn animal8.-The injected material was intro-
duced subcutaneously between the scapulae by passing the needle under the skin
from a point of entry near the root ofthe tail.
Techniqumes ofapplication to the skin.-The area ofdorsal skin to be treated was
kept free of hair by electric clippers. Carcinogens were applied as acetone
solutions in amounts measured by calibrated pipettes.
Ob8ervations.-The number, sizes, and macroscopic appearances of epithelial
and subcutaneous tumours wererecorded atweeklyintervals. Epithelialtumours
thought to be malignant on inspection were removed surgically for histological
examination when they reached 15 mm. diameter. Sick animals were killed. All
skin tumours thought to be malignant, a proportion ofskin tumours thought to be
benign, andallothertumoursweretakenforhistological examinationfrom animals
killed or found dead during the experiments or killed at the termination ofexperi-
ments. Tissues for histological examination were fixed in Bouin's solution,
embedded in paraffin wax, cut at 5 ,u and stained with haematoxylin and eosin.
Experiment I: Effect ofNeonatally Administered MC on Response ofRats
to Topical Applications ofMC
Litters ofnewborn rats were allocated at random to 5 groups for treatment as
shown in Table I. After injection at birth, rats were returned to their mothers
TABLEI.-Experiment I. Details ofTreatment
Group Injected subcutaneously during Applied to dorsal skin between
first day oflife 7 and 57 weeks
1 . 1 mg. in 0-02 ml. 3% . 0.3 ml. of 0.15% MC in acetone twice
aqueous gelatin (a.g.) l weekly for 25 weeks, then 0-3 ml. of
2 . 300 ,ug. MC ,, ,, r 0.3% MC in acetone twice weekly for
3 . 100 pg. MC ,, ,, J 25 weeks
4 . 1 mg. ,, ,, ,, . 0-3 ml. acetone only twice weekly for
50 weeks
5 . 002 ml. a.g. As for Groups 1-3
until weaning. Thereafter they were segregated by sex and treatment group.
Topical applications to the skin were begun when they were 7 weeks old.
The results ofthe experiment are summarized in Tables II, III, and IV.
In females of Groups 1 to 3, which received one subcutaneous injection ofMC
at birth, followed by applications of MC to the skin, both the proportion of rats
whichdeveloped sarcomas andtheaverageinduction-timeforthesetumourstended
to vary directly with the initial dose of MC injected. In males, the incidence of
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sarcomas was similar in Groups 1 and 2 (1 mg. and 300 #tg. MC at birth, respec-
tively) butreductionofthe doseofMC to 100 ,ug. (Group 3) decreasedthe incidence
ofsarcomas and increased the average time oftheir induction to levels comparable
with those in females ofthe same group. In both sexes, neonatal injection ofMC
followed by topical applications of acetone (Group 4) was associated with a lower
incidence of sarcomas than neonatal injection of MC followed by applications of
MC in acetone (Group 1).
These results were analysed by the Gehan modification of the Wilcoxon rank
test, a method which takes into account both incidence and induction time. The
TABLE II.-Experiment I. Injection-site Sarcomas
Number
of rats
alive at
Group weaning
1 . 17 .
15 ?
2 . 18 d
9 ?
3 . 10'
12 ?
4 . 96
12 ?
5 . 18'
14 ?
Treatment
IA
S.c. at
birth
1 mg. MC/a.g.
Applied to
skin from
7th week
MC/acetone
300 pg. MC/a.g. MC/acetone
100 pg. MC/a.g. MC/acetone
1 mg./a.g. Acetone only
Number of rats
which
> developed
sarcomas at
site of
injection
13 6' (76 5%)
12 ? (80.0%)
16 &3 (88*9%)
5? (55-6%)
36' (30 0%)
3 ? (25%)
56 (55 6%)
5? (41-7%)
a.g. only MC/acetone . 0 -
0-
Average age
at death
of sarcoma-
bearing rats
(weeks)
29-5
32-8
31-4
33 -8
57-7
43 -3
24*8
33 0
TABLE III.-Experiment I. Epithelial Skin Tumours
Number,
of rats
alive at
Group weaning
3 . 10' .
12 ?
5 . 186' .
14 ?
Treatment
t I
Injected
at birth
100 ,ug. MC/a.g.
a.g. only
Applied to
skin from
seventh week
MC/acetone
MC/acetone
Number of rats
which
developed
epithelial
skin tumours
10 o' (100%)
10 ? (83.3%)
156' (83.3%)
14 ? (100%)
Average time
of appearance
of first skin
tumours from
start of
application of
MC to skin (weeks)
31 0
34 -2
30.0
30 *4
Times of death of
rats which failed
to develop
epithelial skin
tumours (weeks
from first
application of
MC to skin)
25, 30
24, 28, 28
TABLE IV-Experiment I. Skin Tumour Incidence at Various Times AfterStart
ofTopical Treatment with MC
30 weeks 35 weeks
Treatment ,_A_--"_
Group at birth Sex %TBR* AT/St %TBR AT/S
3 . 100 pg.MC/a.g.. 6' . 50 0-7 . 90 2 5
? . 8-3 0-2 . 30 0.4
5 . a.g. only . 6' . 20 0-3 . 87 3.4
S? . 57 0-8 . 93 3-4 .
* %TBR = Percentage of survivors with skin tumours.
t AT/S = Average number of skin tumours per survivor.
40 weeks
%TBR AT/S
100 8-0
I 100 4.2
100 5-4 .
100 4*0
45 weeks
%TBR AT/S
100 11.9
100 8-0
100 10-0
100 5-6
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outcome of this analysis is depicted in Fig. 1. The risk of sarcoma development
was found to be significantly (0.05 > P > 0.02) less in females of Group 4 than
in females of Group 1. The difference in risk was also significantly (P < 0.01)
less in the females of Group 2 than in the males of the same group. No other
significant differences were found.
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FIG. 1.-Experiment I-Distributions of time to appearance of sarcoma. Analysis bythe Gehan
modification of the Wilcoxon rank test. Each point on the curves was corrected to allow
for deaths from intercurrent disease.
Epithelial skin tumours
Sarcomas tended to arise earlier at the site of injection of MC than epithelial
tumours induced by the application of MC to the skin. Such sarcomas grew
rapidly sothatanimalshadto bekilledwithin 1 to 3 weeksoftheirfirst appearance.
Thus, the development of sarcomas precluded proper analysis ofthe development
ofskin tumours in Groups 1, 2 and 4. The same problem did not arise in animals
of Group 3 (100 ,ug. MC at birth followed by application of MC to skin) or in
Group 5 (aqueous gelatin at birth followed by applications of MC to skin).
Virtually 100 % ofrats in these 2 groups developed epithelial tumours ofthe skin;
the only animals which failed to do so diedearlyinthe experiment as aresulteither
of sarcoma (2 female rats in Group 3) or of intercurrent disease (3 male rats in
Group 5). The average time of appearance ofthe first skin tumour in individual
animals was shorter in rats of Group 5 than those in Group 3, a difference which
was more marked in females (Table III). This was analysed by the Gehan
modification of the Wilcoxon rank test and also by the third Extreme Value
Distribution method; both methods yielded similar results. Among males, there
was no difference between Groups 3 and 5. In females, however, Group 5
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animals developed first skin tumours significantly (P < 0 01) earlier than Group 3
animals.
The enhanced susceptibility of animals in Group 5 as compared with that of
rats in Group 3 is reflected also inthe multiplicity of skin tumours recorded at
35 weeks (Table IV). By the fortieth week, however, this difference had dis-
appeared.
Histological observations
(a) Injection-site tumours.-Most ofthese neoplasms were poorly differentiated
pleomorphic or spindle cell lesions, often with bizarre binucleate and multi-
nucleate cells andregions ofmyxomatous degeneration, haemorrhage and necrosis.
Metastatic deposits of sarcoma were seen in regional lymph nodes and/or lungs in
4 rats-3 from Group 1 and 1 from Group 4.
(b) Epithelial skin tumours.-A wide variety of epithelial neoplasms was
encounted, comprising squamous carcinomas, mixed basi-squamous lesions and
basal cell tumours. The detailed histological structure of these lesions will be
described elsewhere, but the salient features in each group were as follows.
Squamous carcinomas ranged from well-differentiated tumours to anaplastic forms
growing as irregular columns of cells. Dermal invasion was variable in extent
but the panniculus carnosus muscle was always infiltrated. Basi-squamoUs
tumours were occasionally encountered. They were classified into 2 broad
categories according to the predominating type of cell and, in most instances, a
clear preponderance ofbasal or squamous elements was found. Basal cell tumours
were commonly seen and were highly complex in structure. Two main types were
distinguished-" pure" and " mixed " basal cell lesions. The " pure " basal
cell tumours were composed of cells growing either as solid masses or in open
reticular and " adenomatoid " patterns. The " mixed " basal cell tumours
presented an elaborate histological picture with combinations of undifferentiated
basal cells, sebaceous gland elements and hair follicles. Some lesions showed a
wide variety of cell types; others presented a more homogenous appearance in
which hair follicles or sebaceous glands predominated.
Experiment II: Effect ofNeonatally Administered 3,4-benzopyrene (BP) on
Response ofMice to Subsequent Topical Applications ofBP
Newborn mice were allocated to 4 groups for treatment as shown in Table V.
TABLE V.-Experiment II. Details ofTreatment
Injected subcutaneously Applied to dorsal skin
Group during first day of life between 6 and 25 weeks
1 . 40 ug. BP/0-02 ml. a.g. 0-2 ml. 0 025% BP
2 . 10 pg. BP/0-02 ml. a.g. >- in acetone twice weekly
3 . 0 02ml. a.g. J
4 . 40 pg. BP/0 02 ml. a.g. . 0 2 ml. acetone twice
weekly
All mice born on the same day were randomized, irrespective ofthe litter to which
they belonged, between the 4 groups. After injection on the first day oflife, they
were distributed amongst the mothers such that each mother was given neonates
from only 1 group. At weaning, the treated mice were segregated by group and
350MODIFICATION OF RESPONSE TO CARCINOGENS 351
sex. They were vaccinated against ectromelia when 4 weeks old and applications
totheskinwerebegunwhentheywere 6weeksold. Theresultsoftheexperiments
are summarized in Fig. 2 and 3 and Table VI. No sarcomas developed at the
site ofneonatal injection in this experiment.
In the 3 groups which received topical applications of BP, the distributions of
times of development of the first papilloma in individual mice were very similar
(Fig. 2). However, ifdistributions of times of appearance of the first malignant
E
.60
:3
0
U
0~
Weeks after first application of 3,4-Benzopyrene to skin
FIG. 2.-Experiment II-Distributions of time to appearance first papilloma in response to
application of BP to the skin.
TABLE VI.-Experiment II. Average Number of Papillomas and Caroinomas at Various Times
Average number of
papillomas and
carcinomas per
survivor at:
A
22 weeks 26 weeks 30 weeks
0-2 1-6 4.1
0-4 2-6 6 0
0-6 2.2 5-2
Average number
of carcinomas per
survivor at:
30 weeks 36 weeks
0 1 08
0-3 1 7
03 05
Group
1
2
3
4
Treatment
at birth
40 pg. BP/a.g.
10 pg. BP/a.g.
0 *02 ml. a.g.
40 pg. BP
Treatment
from sixth to
twenty-fifth
week of age
BP
BP
BP
Acetone
Number of
animals alive
at 10 weeks
(6' + ?)
34
56
41
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tumour are considered (Fig. 3), there is a significant delay (P < 0-025, for method
of analysis, see Grant, Roe and Pike, 1966) in the group which received 40pg. BP
at birth compared with those receiving 10 ,ug. BP or aqueous gelatin only.
Since these analyses only took account of the first papilloma (or carcinoma)
in each mouse, a further analysis was made. By the use of the Wilcoxon rank
test, the number of tumours (benign and malignant) in the survivors at 26 weeks
and 30 weeks ofage, in males and females separately, and in both sexes combined,
10(
E
0 a
.-co
i' 6C L-
cl
.E
4C
0 4
20
a 40 jug. BP.
10 Ajg. BP.
a.g.
20 25 30
Weeks after first application of 3,4-Benzopyrene to skin
35
FIG. 3.-Experiment II-Distributions of time to appearance of first carcinoma in response
to application of BP.
is shown in Table VII. In males and females there were fewer skin tumours in
the group which received 40 ,tg. BP at birth than in the groups which received
10 ,ug. BP or aqueous gelatin only; these differences were statistically significant
for females at 30 weeks in the 40 ,ug. BP/10 ,tg. BP comparison, for males plus
females at 26 weeks in the 40/tg./10 jug. BP comparison and at 30 weeks for both
40 ,ug. BP/10 ,ug. BP and 40 jug. BP/aqueous gelatin comparisons. Analysis of
malignant tumours bythe Wilcoxon ranktest also indicated asignificantlyreduced
response in the 40 ,ug. BP-treated group.
ol I
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TABLE VII.-Experiment II
Probability that differences between groups in average number of tumours per surviving mouse at different times
after start of skin painting were due to chance (2-tailed significance levels *; a minus sign means that incidence in
the first group is less than that in the second).
Total tumours, benign and malignant
Age
26 weeks 30 weeks
Groups compared (designated A
by treatment 24 hours). Males Females All Males Females All
40 pg. BP/10ug. BP . -0-17 -0 18 -0 04 -0*31 -0o02 -0o01
40 ug BP/a.g. . -0 26 -0 19 -0*18 -0*19 -0*07 -0*03
10 pg. BP/a.g. +0 88 +0-66 +0-48 -0 89 +0 44 +0-58
Malignant tumours
Age
36 weeks
Males Females All
-0 03 -0 03 -0 001
-0 01 -0o44 -0 02
-0 70 +0-26 +0 61
* For the purpose of this analysis animals in the two groups to be compared were ranked according to the number
of skin tumours each bore at the stated time and the significance levels were calculated by the use of the Wilcoxon
rank test.
Some tumours ofother sites were observed; the most common were pulmonary
adenomas which had a higher incidence in the groups receiving 40jpg. BP at
birth irrespective of other treatment. Seven of the mice given BP at birth
developed malignant lymphoma.
Histological observations
The range of tumours encountered was narrower than in the rats of Experi-
ment I. All those regarded as benign were squamous papillomas, some peduncu-
lated, some sessile. Some ofthe sessile tumours showed compression ofthedermis,
and their general appearance suggested that they originated from hair follicles.
All the tumours categorized asmalignantwere squamous carcinomaswhich showed
active invasion of the panniculus carnosus muscle.
Experiment III: Effect ofNeonatally Administered 3-Methylcholanthrene (MC)
on Response of Mice to Subsequent Topical Applications of MC
Newborn mice were allocated to 6 groups for treatment, as shown in Table
VIII. The times at which mice in Groups 1-5 developed their first papillomas
TABLE VIII.-Experiment III. Details ofTreatment
Group Injected subcutaneously durino
first 24 hours of life
1 . 125 jig. MC/0 02 ml. Tricaprylin )
2 . 62 ug. ,, ,, ,
3 . 31 ug. ,,,, } 4 . 0 02 ml. Tricaprylin
5 . No injection
6 . 125 ,ug. MC/0 2 ml. Tricaprylin
Applied to dorsal skin
between 6 and 20 weeks
0*2 ml. 0 1%MC inacetone
twice weekly
0.2 ml. acetone twice weekly
and first carcinomas are depicted in Fig. 4 and 5. No skin tumours developed
in Group 6. The appearance of first papillomas was slightly delayed in Groups 3
and 5, comparedwith othergroups, but there wasno difference in therates atwhich
Groups 1-5 developed first carcinomas. The total number oftumours (benign and
malignant) in surviving animals (Table IX) was analysed by the Wilcoxon rank
test (Table X). Statistically significant differences in both directions were seen
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between groups treated differently at birth but painted similarly with MC from
the age of 6 weeks, and it was impossible to discern a meaningful pattern in the
picture as a whole.
As shown in Fig. 6, sarcomas developed at the site of neonatal injection of
MC in a number ofanimals, the incidence tending to vary directly with the initial
dose of MC. The incidence of sarcomas was highest in the group injected with
125 ,ig. MC at birth which subsequently had MC applied to the skin.
0
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._
E
0
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CL
Weeks after first application of. 3-Methylcholanthrene to skin
FIG. 4.-Experiment III-Distributions of time to appearance of first papilloma in
response to application of MC to the skin.
TABLE IX.-Experiment III. Average Number ofPapillomas and Carcinomas at Various Times
Treatment
from sixth to
twentieth week
of age
Mc
Mc
Mc
Mc
Mc
Number of
animals alive
at 10 weeks
(CT + S)
40
43
43
30
40
Average number of
papillomas and
carcinomas per
survivor at:
16 weeks 21 weeks 26 weeks
0-5 5-0 8-9
0 4 3-3 8-8
0-2 2-0 6-9
0.1 3.4 7.1
0-1 1.8 6-5
Average number
of carcinoma per
survivors at:
A
26 weeks 30 weeks
0-4 1-2
0 4 1-2
0X6 0 9
0-6 1-3
0-5 1-3
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1
2
3
4
5
Treatment
at birth
125 pg. MC
62 ,ug. MC
31 pug. MC
Tricaprylin
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FIG. 5.-Experiment III-Distribution of time to appearance of first carcinoma in
response to application of MC to the skin.
TABLE X.-Experiment III
Probability that difference between groups in average number of tumours per surviving mouse at different times
after start of skin painting were due to chance (2-tailed significance levels *; a minus sign means that incidence in
the first group is less than that in the second.)
Groups compared
(designated by
treatment 24 hrs)
125 jg. MC/
Tricaprylin
125 ug. MC/None
62 pg. MC/
Tricaprylin
62 pg. MC/None
31 pg. MC/
Tricaprylin
31 ug. MC/None
Tricaprylin/None
Benign and Malignant Tumours
f-A
't Malignant Tumours
21 weeks 26 weeks 30 weeks
t ~~~~A A, \, A A
Males Females All Males Females All Males Females All
* +0 08 +0-22 +0 02 +0 20 +0-14 +0*07 . -0-91 -0-35 -0-68
* +0*00006 +004 +0*0001 +0 38 +0*0002 +0-008 . +0-25 -0*05 -0-89
. -0-64 +0-87 -0-79
. +0-05 +0-05 +0-005
--0 03 -0-18 -0-01
. -0-97 +0-75 +0-86
. +0-01 +0-90 +0-003
+0-11 +0-41
+0-22 +0-02
+0- 73 -0-86
-0-91 +0-06
-0-70 +0-20
+0-07 . -0-20 +0-57 -0-62
+0-008 . -0-89 -0-90 -0-84
+0-88 . -0-01 +0-99 -0-10
+0-35 . -0-13 -0-90 -0-16
+0-58 . +0-17 -0-35 +0-70
*See footnote to Table VII.
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FIa. 6.-Experiment III-Distribution of time to appearance of first sarcoma in
response to neonatal injection of MC.
The histological appearances ofskin tumours were similar to those encountered
in Experiment II.
Lung adenomas, usually multiple, arose in response to the neonatal injection
of carcinogen. As in the first experiment with benzopyrene, their incidence varied
with the dose of carcinogen given in the first 24 hours oflife. Six cases ofmalig-
nant lymphoma were encountered in the MC-treated mice but their incidence was
not related to the dose of carcinogen given neonatally.
DISCUSSION
In contrast to the findings reported by Anderson (1962), local sarcomas arose
in rats injected with 1 mg. or 300 jag. MC at birth (Table II). The subsequent
application ofMC to the skin ofrats injected with 1 mg. MC at birth significantly
hastened the appearance of sarcomas (Fig. 1.) In mice, applications ofMC to the
skin enhanced the induction ofsarcomas at the site ofinjection at birth of 125 fig.
MC (Fig. 6). Prehn (1963) reported similar observations.
In Experiment I, 100 jug. MC injected at birth delayed by an average of 4
weeks as compared with solvent-injected controls, the appearance of epithelial
skin tumours in female rats (Tables III and IV). This difference was significant
(P < 0.01). However, no difference of the same kind was seen in males and the
effect of the delay had disappeared by the fortieth week (Table IV). It should
also be stressed that the epithelial tumours induced by MC in Experiment I were
of a variety ofhistological types, and that Anderson's reference to such lesions as
" carcinomata " is equivocal.
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No clear pattern emerged from the results of Experiment III in which mice
were treated with various doses ofMC at birth, and subsequently painted with the
same carcinogen (Fig. 4 and 5 and Tables IX and X). It is possible in this case
that the concentration of MC applied to the skin was too high and that a small
difference in sensitivity in groups treated differently at birth was thereby
obliterated.
Some support for Anderson's (1962) findings came from Experiment II:
40 sag. BP injected at birth significantly delayed the appearance of carcinomas
(Fig. 3) and significantly reduced the average numbers ofpapillomas and carcino-
mas per survivor at various times during the experiment (Tables VI and VII). It
is important to see whether this result can be confirmed.
The experiments described do not, unfortunately, succeed intheirmainpurpose
-namely to define the circumstances under which the phenomenon described by
Anderson (1962) occurs. However, they do show that ifthe neonatal administra-
tion of carcinogens really does reduce the response of animals to subsequent
exposure to the same carcinogen, the reduction is small and depends very much
on the doses of the carcinogen given at birth and subsequently.
We feel that until these conditions have been better defined there is little
point in trying to investigate the mechanism involved.
SUMMARY
In rats, 3-methylcholanthrene (MC) applied to the skin from the age of 7 weeks
significantly enhanced the induction of sarcomas at the site of the subcutaneous
injection of 1 mg. MC on the first day of life.
In females, but not in males, the subcutaneous injection of 100 jug. MC in
aqueous gelatin at birth delayed epithelial tumour-induction in response to the
repeated application of MC to the skin from the seventh week onwards, as
compared with rats injected with aqueous gelatin only at birth.
In mice, MC injected at birth at 3 different dose levels (125 ,ug., 62 ,tg. and
31 pg.) had no consistent effect on skin tumours arising in response to the
subsequent cutaneous application of MC.
In mice, the injection of 40 pg. but not of 10 ,ug. 3,4-benzopyrene (BP) at
birth reduced the number of skin tumours which arose in response to subsequent
weekly applications ofBP to the skin.
The results are discussed in the light ofthose reported by Anderson (1962).
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